SIRAKOSS FDA 510(k) clearance to market Osteo3 ZP Putty, a new nanosynthetic bone graft substitute for filling voids or gaps during spine and trauma bone grafting procedures.
The putty features a unique surface chemistry designed to catalyze rapid and complete bone regeneration.
Osteo3 ZP Putty is an entirely synthetic, nanoporous bone graft substitute comprising novel inorganic granules suspended in a fully synthetic resorbable carrier that can be used directly from the pack. This offers a benefit of less patient time under anaesthetic, yielding lower O.R. time and cost.
“Osteo3 ZP Putty brings patented, best-in-class handling properties to enhance SIRAKOSS’ exceptional nanosynthetic bone regeneration potential, giving surgeons a one-two punch of repair confidence and intraoperative ease-of-use for spine and trauma bone grafting applications,” said Tom Buckland, Director of SIRAKOSS. “U.S. FDA clearance is obviously a major achievement for SIRAKOSS, enabling us to implement the commercial strategy for this game-changing product.”
SIRAKOSS FDA 510(k) clearance to market Osteo3 ZP Putty, a new nanosynthetic bone graft substitute for filling voids or gaps during spine and trauma bone grafting procedures.
The putty features a unique surface chemistry designed to catalyze rapid and complete bone regeneration.
Osteo3 ZP Putty is an entirely synthetic, nanoporous bone...
SIRAKOSS FDA 510(k) clearance to market Osteo3 ZP Putty, a new nanosynthetic bone graft substitute for filling voids or gaps during spine and trauma bone grafting procedures.
The putty features a unique surface chemistry designed to catalyze rapid and complete bone regeneration.
Osteo3 ZP Putty is an entirely synthetic, nanoporous bone graft substitute comprising novel inorganic granules suspended in a fully synthetic resorbable carrier that can be used directly from the pack. This offers a benefit of less patient time under anaesthetic, yielding lower O.R. time and cost.
“Osteo3 ZP Putty brings patented, best-in-class handling properties to enhance SIRAKOSS’ exceptional nanosynthetic bone regeneration potential, giving surgeons a one-two punch of repair confidence and intraoperative ease-of-use for spine and trauma bone grafting applications,” said Tom Buckland, Director of SIRAKOSS. “U.S. FDA clearance is obviously a major achievement for SIRAKOSS, enabling us to implement the commercial strategy for this game-changing product.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
